Caldan Therapeutics Ltd is a spinout company from the University of Glasgow (UofG) and the University of Southern Denmark (SDU), developing novel therapeutics targeting modulators of free fatty acid receptors, for metabolic disease including Type 2 Diabetes (T2D) and other indications.
The spinout opportunity has arisen from a long term collaboration between Professor Graeme Milligan (UofG) and Professor Trond Ulven (SDU).
Free fatty acid receptors have recently emerged as exciting targets for T2D, due to their involvement in multiple aspects of T2D pathophysiology. There may also be potential to explore other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.
Caldan will take advantage of the founders’ world-leading expertise in free fatty acid (FFA) receptor pharmacology and medicinal chemistry, a substantial chemistry package generated over several years of academic research, and proprietary tools for characterising compounds which could provide a key competitive edge.